title: [One hundred fifty autologous peripheral haemopoietic stem cell transplantations and their lessons].
abstract: Five years ago (in September, 2003), the activity of the 5th Haemopoietic Stem Cell Transplantation Centre of Hungary has begun. This centre has been registered as No 648. by the European Group for Blood and Marrow Transplantation-Centres.
  
  
  OBJECTIVE
  To supply the needs of stem cell transplantation regions in north-east Hungary and to develop an active co-operation with the Hungarian and international centres.
  
  
  METHODS
  Transplantations were made according to international criteria.
  
  
  RESULTS
  150 autologous stem cell transplantations has been performed so far, including 74 patients with myeloma multiplex, 43 patients with non-Hodgkin lymphoma, 27 patients with Hodgkin's disease, 4 patients with autoimmune disease, and one patient with leiomyosarcoma. The survival rates were similar to the previous Hungarian and international data. The centre played a role in other activities using stem cell therapy at the University of Debrecen (dendritic cell vaccine program, stem cell therapy in myocardial infarction, stem cell therapy in peripheral arterial- and autoimmune diseases). This centre performed the largest quantity of the conditioning protocol Zevalin, Bischloronitrosourea, Etoposide, cytosine-Arabinoside, Melphalan in non-Hodgkin lymphoma in Hungary; ten patients were treated with this protocol.
authors.affiliation: Debreceni Egyetem, Orvos- és Egészségtudományi Centrum II. Belgyógyászati és III. Belgyógyászati Klinika, Sejtterápia Központ, Debrecen. akiss@dote.hu
authors.forename: Attila
authors.initials: A
authors.lastname: Kiss
authors.forename: Gyula
authors.initials: G
authors.lastname: Reményi
authors.forename: Róbert
authors.initials: R
authors.lastname: Szász
authors.forename: Péter
authors.initials: P
authors.lastname: Batár
authors.forename: László
authors.initials: L
authors.lastname: Rejto
authors.forename: László
authors.initials: L
authors.lastname: Váróczy
authors.forename: Tamás
authors.initials: T
authors.lastname: Sípos
authors.forename: Erika
authors.initials: E
authors.lastname: Kovácsné Kovács
authors.forename: Marianna
authors.initials: M
authors.lastname: Szarvas
authors.forename: Miklós
authors.initials: M
authors.lastname: Udvardy
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000601:surgery; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000601:surgery; D006801:Humans; D006814:Hungary; D007391:International Cooperation; D053208:Kaplan-Meier Estimate; D007890:Leiomyosarcoma / Q000601:surgery; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000601:surgery; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D009607:Nitrosourea Compounds; D003561:Cytarabine; C422802:ibritumomab tiuxetan; D005047:Etoposide; D008558:Melphalan